Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the development and potential therapeutic applications of steroid sulfatase inhibitors for hormone-dependent disorders and cognitive dysfunction, reporting no new clinical results.

Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.

This article suggests using oral contraceptives with antiandrogenic properties for women with virilization symptoms like acne and advises higher doses of antiandrogens for severe acne, androgenic alopecia, or idiopathic hirsutism.

This study reports that oral spironolactone may be a useful and low-cost first-line treatment for hidradenitis suppurativa in women, with relatively few side effects.

The treatment slightly increased hair growth and was safe for most women.

This article discusses the use of topical estrogen therapy for androgenetic alopecia in menopausal females and reports no new clinical results.

In this study, hirsute women treated with cyproterone acetate and ethinyloestradiol experienced significant reductions in sebum secretion and hair growth after several months.

This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.

This abstract reviews the use of spironolactone as a treatment for hormonal acne, female pattern hair loss, and hirsutism due to its antiandrogenic properties and favorable side effect profile, highlighting its value in dermatological therapies.

This study explored the use of SOD-loaded niosomes as carriers to enhance the delivery of superoxide dismutase into hair follicles on guinea pig skin, finding that niosomes improved SOD penetration and preservation compared to free SOD, suggesting their potential as effective delivery vehicles.

This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.

This study found that after 12 weeks of taking 10 mg of S-equol daily, over 90% of participating perimenopausal and menopausal women reported improvements in symptoms like hot flashes, night sweats, and sleep disturbances.

This review discusses spironolactone's dermatologic applications, particularly for conditions like hirsutism and female pattern hair loss, but reports no new results; it also highlights safety concerns in pregnancy and men.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study reported that treatment with cyproterone acetate alone and then with incremental estrogen doses induced mild feminizing effects in late-pubertal trans-girls, with further feminization observed after adding estrogen.

This study observed that spironolactone improved hidradenitis suppurativa in over 80% of female patients at 3 and 6 months, with no significant differences in response due to menstrual flares or polycystic ovarian syndrome, but mild adverse events were reported.

This article reviews non-biodegradable progestational subdermal implants as long-acting contraceptives for women, discussing their effectiveness, associated side effects, and implementation challenges without reporting new clinical results.

In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.

In this study, patients with testicular feminization syndrome showed limited anabolic responsiveness to dihydrotestosterone, potentially due to reduced affinity of nuclear receptor sites for androgenic steroids rather than defective testosterone conversion.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

This study found that GnRH-a treatment or orchiectomy, which required significantly lower doses of oral estradiol valerate, were more effective than anti-androgens like spironolactone and finasteride in achieving target hormone levels in transgender females in India.

In a retrospective study, researchers found that topical spironolactone improved tear film quality and reduced inflammation related to meibomian gland dysfunction and evaporative dry eye in patients, demonstrating good tolerability and suggesting it as a potential therapy for managing the condition.

This study found that serum 3 alpha-diol G levels in women with idiopathic hirsutism correlated well with their clinical response to treatment, suggesting its usefulness in evaluating treatment outcomes.

Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.

This article discusses hyperandrogenism syndrome in women, highlighting systemic antiandrogenic therapy as advisable for severe or moderate hirsutism but reports no new clinical results.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

This retrospective study found that cyproterone acetate, both alone and with estrogens, was safe, well tolerated, and induced modest feminizing effects in late-pubertal transgender female adolescents.